Le H Hua, Carrie M Hersh, Lana Zhovtis Ryerson, Nick Belviso, Megan Vignos
{"title":"老年多发性硬化症患者接受干扰素β -1a或聚乙二醇干扰素β -1a治疗的结果","authors":"Le H Hua, Carrie M Hersh, Lana Zhovtis Ryerson, Nick Belviso, Megan Vignos","doi":"10.1080/17582024.2025.2527558","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The peak prevalence of multiple sclerosis (MS) is shifting to older patients. Using real-world data, we describe outcomes among older (≥60 years) and younger patients treated with interferon beta-1a or no disease-modifying therapy (no-DMT).</p><p><strong>Methods: </strong>Assessments over 24 months included annualized relapse rates (ARRs), patient-reported disability outcomes, and MS Performance Test (MSPT) outcomes.</p><p><strong>Results: </strong>The study included 767 interferon-treated and 2783 no-DMT patients. ARR over 24 months was lower for the older and younger interferon-treated patients than the no-DMT patients. Mean change in Patient-Determined Disease Steps (PDDS) from baseline-24 months was -0.13 (1.08) in older interferon-treated patients vs 0.20 (1.30) in older no-DMT patients.</p><p><strong>Conclusion: </strong>Over 24 months ARR remained low and disability progression was stable for interferon-treated patients aged ≥ 60 years.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-9"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.\",\"authors\":\"Le H Hua, Carrie M Hersh, Lana Zhovtis Ryerson, Nick Belviso, Megan Vignos\",\"doi\":\"10.1080/17582024.2025.2527558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The peak prevalence of multiple sclerosis (MS) is shifting to older patients. Using real-world data, we describe outcomes among older (≥60 years) and younger patients treated with interferon beta-1a or no disease-modifying therapy (no-DMT).</p><p><strong>Methods: </strong>Assessments over 24 months included annualized relapse rates (ARRs), patient-reported disability outcomes, and MS Performance Test (MSPT) outcomes.</p><p><strong>Results: </strong>The study included 767 interferon-treated and 2783 no-DMT patients. ARR over 24 months was lower for the older and younger interferon-treated patients than the no-DMT patients. Mean change in Patient-Determined Disease Steps (PDDS) from baseline-24 months was -0.13 (1.08) in older interferon-treated patients vs 0.20 (1.30) in older no-DMT patients.</p><p><strong>Conclusion: </strong>Over 24 months ARR remained low and disability progression was stable for interferon-treated patients aged ≥ 60 years.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17582024.2025.2527558\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17582024.2025.2527558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.
Background: The peak prevalence of multiple sclerosis (MS) is shifting to older patients. Using real-world data, we describe outcomes among older (≥60 years) and younger patients treated with interferon beta-1a or no disease-modifying therapy (no-DMT).
Methods: Assessments over 24 months included annualized relapse rates (ARRs), patient-reported disability outcomes, and MS Performance Test (MSPT) outcomes.
Results: The study included 767 interferon-treated and 2783 no-DMT patients. ARR over 24 months was lower for the older and younger interferon-treated patients than the no-DMT patients. Mean change in Patient-Determined Disease Steps (PDDS) from baseline-24 months was -0.13 (1.08) in older interferon-treated patients vs 0.20 (1.30) in older no-DMT patients.
Conclusion: Over 24 months ARR remained low and disability progression was stable for interferon-treated patients aged ≥ 60 years.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
